ObsEva, a Swiss biopharmaceutical company developing drugs that address serious conditions compromising pregnancy from conception to birth, has made two new appointments to its management team.
Elke Bestel joins the firm as Chief Medical Officer and Head of Pharmacovigilance bringing 19 years of experience in pharmaceutical product development to the role.
Prior to joining ObsEva, Bestel was CMO at PregLem, a Swiss speciality biopharmaceutical company. Prior to this, she worked for Galderma, France, where she was responsible for clinical studies as well as development, registration and life-cycle activities of dermatological products. Before joining Galderma, she worked at the clinical research organisation MDS, France where she was responsible for the conduct of clinical studies from Phase I to III.
Jean-Pierre Gotteland joins ObsEva as Chief Scientific Officer. He has more than 20 years' experience in the pharmaceutical industry in all product development stages particularly research, preclinical development and early clinical development.
After an early career at Pierre Fabre Medicament (France), Gotteland joined Serono in 1998 (subsequently Merck Serono) where he was responsible for various research and preclinical development programmes in the areas of neurology, autoimmune disorders, endocrinology, metabolism and oncology. In 2007, he was one of the first employees to join PregLem. as VP Non Clinical Development and CMC, then Chief Development Officer.
